financetom
Business
financetom
/
Business
/
GMM Pfaudler Q4: Strong performance, On track to meet FY25 guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GMM Pfaudler Q4: Strong performance, On track to meet FY25 guidance
May 26, 2023 3:07 AM

GMM Pfaudler posted a strong performance in the fourth quarter on May 25 with revenues at Rs 866 crore, up 24 percent year on year. The earnings before interest, tax, depreciation and amortisation (EBITDA) grew 35 percent to Rs 96 crore. EBITDA margins improved 90 bps to 11.1 percent versus 10.2 percent in the corresponding quarter of last year.

Share Market Live

NSE

The net profits more than doubled to Rs 36 crore in the fourth quarter. This includes Rs 19 crore of exceptional Mumbai property sales. The stock is trading 1 percent higher on the exchanges at noon on May 26.

Also read: Cummins India Q4 Strong performance, cautiously optimistic on demand

GMM Pfaudler won Rs 792 crore orders in the fourth quarter and a total of Rs 3,392 crore orders in FY23, up 15 percent, ending the year with an order backlog of Rs 2,162 crore, up 12 percent.

The company said that despite the challenging global environment, it has a strong opportunity pipeline and outlook remains positive. Mr. Tarak Patel, Managing Director said, “During the year, we completed the acquisition of Hydro Air Research Italia S.r.l, Italy, JDS Manufacturing Inc., USA and Mixel Group (France & China), which reinforces our strategy of expanding our product portfolio.”

The Board recommended a final dividend of Rs 1 per equity share and total dividend for FY23 (including interim dividend) would be Rs 2 per equity share.

Also read: Five questions that Siemens minority shareholders seek answers to

The company had earlier set a target for FY25 revenues of Rs 3,700 crore and EBITDA of Rs 630 crore. Axis Capital says the revenue target is achievable with implied 8 percent revenue CAGR over the next two years. However, achieving the EBITDA guidance is challenging as it implies a 17 percent EBITDA margin guidance. The brokerage adds "This would be premised on standalone margin improving from 15.9 percent in FY23 to 20 percent

in the next two years and others margin improving from 12.4 percent in FY23 to 15 percent plus over the next couple of years." Axis Capital has a Buy rating on the stock with a target price of Rs 2,600 implying 77 percent upside.

Also read: Patel family becomes single largest promoter shareholder in GMM Pfaudler

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vox Royalty Executes Binding Deal to Acquire Wyloo North Iron Ore Royalty in Western Australia for $1 Million
Vox Royalty Executes Binding Deal to Acquire Wyloo North Iron Ore Royalty in Western Australia for $1 Million
Aug 25, 2025
09:58 AM EDT, 08/25/2025 (MT Newswires) -- Vox Royalty ( VOXR ) said Monday that it has executed a binding agreement to purchase an iron ore royalty over the Wyloo North iron ore project in the Pilbara region of western Australia from an Australian company for 1.5 million Australian dollars ($974,497). The project is currently operated by Fortescue Metals Group,...
Flutter Stops Real-Money Gaming Operations in India Following New Law
Flutter Stops Real-Money Gaming Operations in India Following New Law
Aug 25, 2025
09:57 AM EDT, 08/25/2025 (MT Newswires) -- Flutter Entertainment ( FLUT ) said Monday it has stopped its real-money gaming operations in India after the country passed a law prohibiting real-money gaming products on Friday. The company said its Indian business was expected to contribute about $200 million in revenue and $50 million in adjusted earnings before interest, taxes, depreciation...
What's Going On With Coya Therapeutics Stock?
What's Going On With Coya Therapeutics Stock?
Aug 25, 2025
Shares of Coya Therapeutics Inc ( COYA ) are trading higher Monday morning after the company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis (ALS). What To Know: The Houston-based clinical-stage biotechnology company is trending across social media platforms after revealing that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New...
BioRem Up 10% Q2 Net Earnings More Than Doubles; Expects Backlog To Support Growth In Second Half
BioRem Up 10% Q2 Net Earnings More Than Doubles; Expects Backlog To Support Growth In Second Half
Aug 25, 2025
09:59 AM EDT, 08/25/2025 (MT Newswires) -- BioRem ( BIRMF ) was up 10% at last look on Monday after saying second-quarter net earnings more than doubled on higher revenue, and it expects backlog to support strong revenues and earnings in the second half of the year. The company, which manufactures air emissions control systems used to eliminate odors, and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved